Throw­ing in the tow­el, trou­bled an­tibi­ot­ic mak­er Ar­a­digm files for Chap­ter 11

One year ago, a cash-strapped Ar­a­digm let go of its CEO, CFO and CMO in a fi­nal at­tempt to re­vive the com­pa­ny fol­low­ing a dev­as­tat­ing FDA re­jec­tion for its in­haled an­tibi­ot­ic. De­spite ex­ec­u­tive chair­man John Siebert’s best ef­forts, things seem to have gone down­hill since then: Ar­a­digm be­gan the year with the ac­knowl­edge­ment that its stock has tum­bled from the Nas­daq to an over-the-counter mar­ket. To­day, it’s of­fi­cial­ly de­clar­ing bank­rupt­cy to sell off what re­mains of its spe­cial­ty phar­ma busi­ness.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA